Biovica International announced that the company has received a PLA code from the AMA (American Medical Association), an important milestone in the commercialization of DiviTum® TKa in the United States. The PLA code is a specific code for the DiviTum® TKa test issued by the AMA and enables payers and providers to readily identify service and reduce administrative burden for providers and payers. Effective October 1, 2023, the code will be used for billing, reporting, and processing healthcare claims.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.706 SEK | +6.36% | -22.81% | -33.88% |
Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.88% | 13.08M | |
-20.45% | 10.82B | |
+43.17% | 3.25B | |
-35.86% | 2.11B | |
-17.21% | 2.08B | |
-29.81% | 1.48B | |
+17.56% | 1.02B | |
-4.37% | 733M | |
-37.00% | 391M | |
-46.94% | 377M |
- Stock Market
- Equities
- BIOVIC B Stock
- News Biovica International AB
- Biovica International Achieves PLA code for Medicare